Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
Phase 3
Completed
- Conditions
- Postmenopausal Vaginal AtrophyMenopause
- First Posted Date
- 2005-04-20
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 309
- Registration Number
- NCT00108849
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Winnipeg, Canada
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Phase 2
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00108758
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Capa-ISTANBUL, Turkey
Trial of NovoSeven® in Haemophilia - Joint Bleeds
Phase 4
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00108797
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 389
- Registration Number
- NCT00106366
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Dose Response to Recombinant Factor VIIa When Administered for Bleed
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHealthy
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00104455
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 503
- Registration Number
- NCT00104182
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valladolid, Spain
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
Phase 3
Completed
- Conditions
- Pituitary DwarfismGrowth Hormone Disorder
- First Posted Date
- 2005-02-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 149
- Registration Number
- NCT00102817
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Use of Activated Recombinant FVII in Spinal Surgery
Phase 2
Completed
- Conditions
- Acquired Bleeding DisorderSpinal Fusion
- First Posted Date
- 2005-01-20
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 50
- Registration Number
- NCT00102037
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4877
- Registration Number
- NCT00101751
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 293
- Registration Number
- NCT00097877
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Santurce, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath